Clinical Trial

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-01; most recent amendment 2025-01-16.
Status change: Recruiting → Active, Not Recruiting 2025-01-16
Trial Details
NCT Number NCT06299124
Lead Sponsor Regor Pharmaceuticals Inc.
Conditions Breast Cancer, Advanced Solid Tumor
Enrollment 40 participants
Start Date 2023-04-17
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-20